Since the initial clinical approval in the late 1990s and remarkable anticancer effects for
certain types of cancer, molecular targeted therapy utilizing small molecule agents or …

Receptor tyrosine kinases (RTKs) are key regulatory signaling proteins governing cancer
cell growth and metastasis. During the last two decades, several molecules targeting RTKs …

In the ENESTnd study, with≥ 10 years follow-up in patients with newly diagnosed chronic
myeloid leukemia (CML) in chronic phase, nilotinib demonstrated higher cumulative …

Asciminib, the first BCR:: ABL1 inhibitor that S pecifically T argets the A BL M yristoyl P ocket
(STAMP), is approved worldwide for the treatment of adults with Philadelphia chromosome …

Bcr-Abl inhibitors paved the way of targeted therapy epoch. Imatinib was the first tyrosine
kinase inhibitor to be discovered with high specificity for Bcr-Abl protein resulting from t (9 …

Simple Summary Chronic myeloid leukemia (CML) is a myeloproliferative neoplasia
associated with a molecular alteration, the fusion gene BCR-ABL1, that encodes the tyrosine …

Chronic myeloid leukemia (CML) is driven by the BCR-ABL1 fusion protein, formed by a
translocation between chromosomes 9 and 22 that creates the Philadelphia chromosome …

Abstract Treatment-free remission (TFR) in patients with chronic myeloid leukemia in chronic
phase (CML-CP) is considered a feasible option, especially with the ability of second …

Background After discontinuing ruxolitinib, the outcome of patients with myelofibrosis
reportedly has been poor. The authors investigated whether disease characteristics before …

Background The major complication of COVID-19 is hypoxaemic respiratory failure from
capillary leak and alveolar oedema. Experimental and early clinical data suggest that the …